NEW YORK, Feb. 21 - ArQule will apply the computational compound design system it co-designed with SignalGene to its own p38 MAP kinase drug-discovery program, the two companies said on Thursday.
The firms agreed in January 2001 to develop this system, and as part of that agreement will now apply it to design, generate, and evaluate new compounds that target p38 MAP kinase.
ArQule will produce the new compounds and test them for biological activity. The company has development rights to these compounds.
SignalGene, in return, will receive research fees and milestone payments for any relevant new compounds.
The system that the two companies developed employs interaction data and 3-D structure knowledge in order to come up with new drugs.